Abstract
This phase II study was conducted to determine the response and toxicity of gemcitabine (2',2'-difluorodeoxycytidine) in chemotherapy-naive patients with non-small-cell lung cancer (NSCLC). A group of 73 patients were entered into the study. The patients had received no previous chemotherapy and all had measurable disease. The initial starting dose of gemcitabine was 1000 mg/m2 per week x 3 followed by a week of rest, and was escalated for the next cycle to 1250 mg/m2, provided there were no signs of hematologic toxicity (WBC < 3000/microl and/or platelets < 70,000/microl) in the previous cycle. Among 73 eligible patients, there were 19 partial responses (PRs), with an overall response rate of 26.0% (95% confidence interval 16.5-37.6%). The response rate for stage IIIa and IIIb disease was significantly higher than that for stage IV disease [41.4% (12/29) vs 15.9% (7/44); P = 0.028]. The median duration of response in patients showing a PR was 4.6 months (1.7 10.4 months). The median number of cycles given was two per patient (range one to seven). Grade 3 anemia, leukopenia and neutropenia occurred in 15 patients (20.5%), 7 patients (9.6%) and 20 patients (27.4%), respectively. Grade 3 thrombocytopenia occurred in one patient (...Continue Reading
Citations
Aug 21, 2013·Advanced Drug Delivery Reviews·Bin Sheng WongGiorgia Pastorin
Feb 13, 1999·European Journal of Pharmacology·J RiegerM Weller
Jul 6, 2000·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·J P SculierJ Klastersky
Feb 17, 2000·Australian and New Zealand Journal of Medicine·J R DavisJ R Zalcberg
Feb 6, 2014·The International Journal of Biochemistry & Cell Biology·Christakis PanayiotouAnna Karlsson
Jan 30, 2007·The Journal of Thoracic and Cardiovascular Surgery·Tatsuya YoshimasuTomoko Furukawa
Mar 21, 2002·Clinics in Chest Medicine·Tracy E Kim, John R Murren
Oct 2, 2003·British Journal of Cancer·F M WachtersH J M Groen
Sep 19, 2015·Clinical Medicine Insights. Oncology·Célia TurcoChristophe Borg
Mar 23, 2011·Pharmacoepidemiology and Drug Safety·Shuko NojiriTakumi Kishimoto
Nov 26, 1999·British Journal of Cancer·W ZoliD Amadori
Apr 3, 1999·Current Opinion in Oncology·K NishioN Saijo
Apr 23, 2005·Japanese Journal of Clinical Oncology·Kaoru MatsuiMasahiro Fukuoka
Nov 27, 2002·Cancer Investigation·Rachel Ash-BernalRodrigo Erlich
Sep 25, 2019·Seminars in Cancer Biology·Sadhna AggarwalSubash Chandra Gupta